Cullinan Therapeutics (CGEM) announced that the U.S. Food and Drug Administration has granted Fast Track designation to CLN-049 for the treatment of relapsed/refractory acute myeloid leukemia. Data from the Phase 1 clinical trial of CLN-049 will be presented at the upcoming 67th American Society of Hematology Annual Meeting and Exposition in an oral presentation on December 8.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential
- Cullinan Therapeutics price target raised to $38 from $32 at BTIG
- Cullinan Management Ends Development of CLN-617
- Promising Developments and Strategic Partnerships Boost Cullinan Management’s Growth Prospects
- Taiho, Cullinan Therapeutics initiate rolling submission of NDA for zipalertinib